IQVIA Holdings Key Executives
This section highlights IQVIA Holdings's key executives, including their titles and compensation details.
Find Contacts at IQVIA Holdings
(Showing 0 of )
IQVIA Holdings Earnings
This section highlights IQVIA Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-06 | $3.11 | $3.12 |
| Read Transcript | Q3 | 2024 | 2024-10-31 | $2.82 | $2.84 |
| Read Transcript | Q2 | 2024 | 2024-07-22 | $2.56 | $2.64 |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $2.49 | $2.54 |
| Read Transcript | Q4 | 2023 | 2024-02-14 | $2.82 | $2.84 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | $2.46 | $2.49 |
| Read Transcript | Q2 | 2023 | 2023-08-01 | $2.37 | $2.43 |
| Read Transcript | Q1 | 2023 | 2023-04-27 | $2.41 | $2.45 |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
$185.89
Stock Price
$32.78B
Market Cap
88.00K
Employees
Durham, NC
Location
Financial Statements
Access annual & quarterly financial statements for IQVIA Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B |
| Cost of Revenue | $10.03B | $9.74B | $9.38B | $9.23B | $7.50B |
| Gross Profit | $5.38B | $5.24B | $5.03B | $4.64B | $3.86B |
| Gross Profit Ratio | 34.89% | 35.00% | 34.89% | 33.50% | 33.97% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.99B | $2.05B | $2.07B | $1.96B | $1.79B |
| Other Expenses | $1.18B | $1.21B | $1.13B | $1.26B | $1.29B |
| Operating Expenses | $3.17B | $3.26B | $3.20B | $3.23B | $3.08B |
| Cost and Expenses | $13.20B | $13.01B | $12.58B | $12.46B | $10.58B |
| Interest Income | $47.00M | $36.00M | $13.00M | $6.00M | $6.00M |
| Interest Expense | $670.00M | $672.00M | $416.00M | $375.00M | $416.00M |
| Depreciation and Amortization | $1.11B | $1.12B | $1.13B | $1.26B | $1.29B |
| EBITDA | $3.45B | $3.30B | $2.89B | $2.75B | $2.06B |
| EBITDA Ratio | 22.41% | 22.04% | 20.38% | 20.28% | 18.85% |
| Operating Income | $2.20B | $1.98B | $1.80B | $1.39B | $731.00M |
| Operating Income Ratio | 14.29% | 13.19% | 12.48% | 10.04% | 6.44% |
| Total Other Income Expenses Net | $-533.00M | $-518.00M | $-436.00M | $-265.00M | $-358.00M |
| Income Before Tax | $1.67B | $1.46B | $1.36B | $1.13B | $373.00M |
| Income Before Tax Ratio | 10.83% | 9.74% | 9.46% | 8.13% | 3.28% |
| Income Tax Expense | $301.00M | $101.00M | $260.00M | $163.00M | $72.00M |
| Net Income | $1.37B | $1.36B | $1.09B | $966.00M | $279.00M |
| Net Income Ratio | 8.91% | 9.06% | 7.57% | 6.96% | 2.46% |
| EPS | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 |
| EPS Diluted | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 |
| Weighted Average Shares Outstanding | 181.30M | 183.80M | 187.60M | 191.40M | 191.30M |
| Weighted Average Shares Outstanding Diluted | 183.40M | 186.30M | 190.60M | 195.00M | 195.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.96B | $3.90B | $3.81B | $3.74B | $3.91B | $3.74B | $3.73B | $3.65B | $3.74B | $3.56B | $3.54B | $3.57B | $3.64B | $3.39B | $3.44B | $3.41B | $3.30B | $2.79B | $2.52B | $2.75B |
| Cost of Revenue | $2.58B | $2.52B | $2.76B | $2.71B | $2.79B | $2.43B | $2.44B | $2.40B | $2.41B | $2.32B | $2.33B | $2.32B | $2.36B | $2.25B | $2.32B | $2.29B | $2.17B | $1.80B | $1.70B | $1.82B |
| Gross Profit | $1.38B | $1.38B | $1.06B | $1.03B | $1.11B | $1.31B | $1.28B | $1.25B | $1.33B | $1.24B | $1.21B | $1.25B | $1.27B | $1.14B | $1.11B | $1.12B | $1.13B | $986.00M | $817.00M | $930.00M |
| Gross Profit Ratio | 34.82% | 35.40% | 27.70% | 27.60% | 28.50% | 35.10% | 34.50% | 34.30% | 35.60% | 34.80% | 34.20% | 34.90% | 35.00% | 33.60% | 32.40% | 32.70% | 34.14% | 35.39% | 32.41% | 33.77% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $407.00M | $- | $- | $407.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $84.00M | $- | $- | $- |
| Selling General and Administrative Expenses | $453.00M | $522.00M | $509.00M | $508.00M | $556.00M | $502.00M | $482.00M | $513.00M | $583.00M | $517.00M | $483.00M | $488.00M | $542.00M | $498.00M | $482.00M | $442.00M | $491.00M | $460.00M | $431.00M | $407.00M |
| Other Expenses | $299.00M | $306.00M | $67.00M | $-11.00M | $47.00M | $35.00M | $16.00M | $253.00M | $357.00M | $248.00M | $270.00M | $255.00M | $2.00M | $62.00M | $29.00M | $37.00M | $6.00M | $14.00M | $32.00M | $13.00M |
| Operating Expenses | $752.00M | $828.00M | $509.00M | $508.00M | $556.00M | $799.00M | $741.00M | $766.00M | $940.00M | $765.00M | $753.00M | $743.00M | $804.00M | $834.00M | $825.00M | $765.00M | $835.00M | $779.00M | $739.00M | $723.00M |
| Cost and Expenses | $3.33B | $3.32B | $3.27B | $3.22B | $3.35B | $3.23B | $3.18B | $3.16B | $3.35B | $3.09B | $3.08B | $3.07B | $3.17B | $3.09B | $3.15B | $3.06B | $3.01B | $2.58B | $2.44B | $2.55B |
| Interest Income | $11.00M | $13.00M | $12.00M | $11.00M | $12.00M | $14.00M | $4.00M | $6.00M | $6.00M | $4.00M | $2.00M | $1.00M | $2.00M | $2.00M | $1.00M | $1.00M | $2.00M | $1.00M | $1.00M | $2.00M |
| Interest Expense | $171.00M | $170.00M | $163.00M | $166.00M | $193.00M | $181.00M | $169.00M | $141.00M | $128.00M | $108.00M | $94.00M | $86.00M | $90.00M | $92.00M | $94.00M | $99.00M | $102.00M | $100.00M | $108.00M | $106.00M |
| Depreciation and Amortization | $303.00M | $278.00M | $269.00M | $264.00M | $316.00M | $297.00M | $259.00M | $253.00M | $357.00M | $248.00M | $270.00M | $255.00M | $262.00M | $336.00M | $343.00M | $323.00M | $344.00M | $319.00M | $308.00M | $316.00M |
| EBITDA | $1.02B | $798.00M | $817.00M | $767.00M | $844.00M | $808.00M | $803.00M | $741.00M | $782.00M | $724.00M | $727.00M | $757.00M | $734.00M | $701.00M | $633.00M | $674.00M | $640.00M | $526.00M | $386.00M | $523.00M |
| EBITDA Ratio | 25.72% | 20.48% | 21.42% | 21.07% | 22.38% | 22.94% | 22.08% | 21.17% | 20.67% | 20.21% | 19.66% | 20.96% | 20.19% | 20.76% | 19.28% | 20.89% | 19.50% | 19.42% | 16.62% | 19.54% |
| Operating Income | $626.00M | $550.00M | $548.00M | $524.00M | $559.00M | $481.00M | $524.00M | $471.00M | $379.00M | $472.00M | $453.00M | $495.00M | $463.00M | $302.00M | $286.00M | $342.00M | $289.00M | $187.00M | $62.00M | $193.00M |
| Operating Income Ratio | 15.82% | 14.12% | 14.37% | 14.01% | 14.30% | 12.87% | 14.06% | 12.90% | 10.14% | 13.25% | 12.79% | 13.87% | 12.73% | 8.91% | 8.32% | 10.03% | 8.76% | 6.71% | 2.46% | 7.01% |
| Total Other Income Expenses Net | $-82.00M | $-201.00M | $-84.00M | $-166.00M | $-128.00M | $-132.00M | $-149.00M | $-109.00M | $-104.00M | $-112.00M | $-125.00M | $-95.00M | $-87.00M | $-29.00M | $-64.00M | $-85.00M | $-95.00M | $-85.00M | $-87.00M | $-91.00M |
| Income Before Tax | $544.00M | $349.00M | $436.00M | $340.00M | $373.00M | $349.00M | $375.00M | $362.00M | $275.00M | $360.00M | $328.00M | $400.00M | $376.00M | $273.00M | $222.00M | $257.00M | $194.00M | $102.00M | $-25.00M | $102.00M |
| Income Before Tax Ratio | 13.74% | 8.96% | 11.43% | 9.09% | 9.54% | 9.34% | 10.06% | 9.91% | 7.35% | 10.11% | 9.26% | 11.21% | 10.34% | 8.05% | 6.46% | 7.54% | 5.88% | 3.66% | -0.99% | 3.70% |
| Income Tax Expense | $112.00M | $65.00M | $75.00M | $49.00M | $-102.00M | $51.00M | $81.00M | $71.00M | $48.00M | $70.00M | $71.00M | $71.00M | $59.00M | $12.00M | $48.00M | $44.00M | $63.00M | $-3.00M | $-5.00M | $17.00M |
| Net Income | $437.00M | $285.00M | $363.00M | $288.00M | $469.00M | $303.00M | $297.00M | $289.00M | $227.00M | $283.00M | $256.00M | $325.00M | $318.00M | $261.00M | $175.00M | $212.00M | $119.00M | $101.00M | $-23.00M | $82.00M |
| Net Income Ratio | 11.04% | 7.32% | 9.52% | 7.70% | 12.00% | 8.11% | 7.97% | 7.91% | 6.07% | 7.94% | 7.23% | 9.11% | 8.75% | 7.70% | 5.09% | 6.22% | 3.61% | 3.63% | -0.91% | 2.98% |
| EPS | $2.41 | $1.57 | $1.99 | $1.58 | $2.58 | $1.66 | $1.61 | $1.56 | $1.22 | $1.52 | $1.36 | $1.71 | $1.67 | $1.36 | $0.91 | $1.11 | $0.62 | $0.53 | $-0.12 | $0.43 |
| EPS Diluted | $2.38 | $1.55 | $1.97 | $1.56 | $2.54 | $1.63 | $1.59 | $1.53 | $1.20 | $1.49 | $1.34 | $1.68 | $1.63 | $1.34 | $0.90 | $1.09 | $0.62 | $0.52 | $-0.12 | $0.42 |
| Weighted Average Shares Outstanding | 181.30M | 182.10M | 182.20M | 181.90M | 181.90M | 182.90M | 184.40M | 185.80M | 185.70M | 186.50M | 188.30M | 190.00M | 190.80M | 191.50M | 191.60M | 191.50M | 191.30M | 191.30M | 190.90M | 191.60M |
| Weighted Average Shares Outstanding Diluted | 183.40M | 184.20M | 184.30M | 184.30M | 184.30M | 185.50M | 186.70M | 188.60M | 188.60M | 189.40M | 191.10M | 193.40M | 194.80M | 195.30M | 194.90M | 194.90M | 191.30M | 194.90M | 190.90M | 195.70M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.70B | $1.38B | $1.22B | $1.37B | $1.81B |
| Short Term Investments | $141.00M | $120.00M | $93.00M | $111.00M | $88.00M |
| Cash and Short Term Investments | $1.70B | $1.50B | $1.31B | $1.48B | $1.90B |
| Net Receivables | $3.80B | $3.41B | $2.96B | $2.61B | $2.47B |
| Inventory | $- | $- | $151.00M | $156.00M | $159.00M |
| Other Current Assets | $331.00M | $687.00M | $712.00M | $677.00M | $722.00M |
| Total Current Assets | $5.83B | $5.60B | $4.98B | $4.76B | $5.09B |
| Property Plant Equipment Net | $773.00M | $819.00M | $863.00M | $903.00M | $953.00M |
| Goodwill | $14.71B | $14.57B | $13.92B | $13.30B | $12.65B |
| Intangible Assets | $4.50B | $4.84B | $4.82B | $4.94B | $5.21B |
| Goodwill and Intangible Assets | $19.21B | $19.41B | $18.74B | $18.24B | $17.86B |
| Long Term Investments | $108.00M | $239.00M | $162.00M | $164.00M | $162.00M |
| Tax Assets | $194.00M | $166.00M | $118.00M | $124.00M | $114.00M |
| Other Non-Current Assets | $786.00M | $455.00M | $472.00M | $491.00M | $386.00M |
| Total Non-Current Assets | $21.07B | $21.09B | $20.36B | $19.93B | $19.47B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B |
| Account Payables | $736.00M | $709.00M | $645.00M | $621.00M | $581.00M |
| Short Term Debt | $1.15B | $825.00M | $152.00M | $91.00M | $149.00M |
| Tax Payables | $156.00M | $116.00M | $161.00M | $137.00M | $102.00M |
| Deferred Revenue | $- | $1.80B | $1.80B | $1.82B | $1.25B |
| Other Current Liabilities | $4.92B | $3.15B | $2.82B | $2.57B | $2.47B |
| Total Current Liabilities | $6.96B | $6.49B | $5.58B | $5.24B | $4.56B |
| Long Term Debt | $346.00M | $13.41B | $13.08B | $12.35B | $12.76B |
| Deferred Revenue Non-Current | $- | $- | $464.00M | $- | $- |
| Deferred Tax Liabilities Non-Current | $196.00M | $202.00M | $464.00M | $410.00M | $338.00M |
| Other Non-Current Liabilities | $13.33B | $470.00M | $447.00M | $649.00M | $633.00M |
| Total Non-Current Liabilities | $13.88B | $14.08B | $13.99B | $13.41B | $13.73B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $20.83B | $20.57B | $19.57B | $18.65B | $18.28B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $11.14B | $3.00M | $10.90B | $10.78B | $11.10B |
| Retained Earnings | $6.07B | $4.69B | $3.33B | $2.24B | $1.28B |
| Accumulated Other Comprehensive Income Loss | $-1.04B | $-867.00M | $-727.00M | $-406.00M | $-205.00M |
| Other Total Stockholders Equity | $-10.10B | $2.28B | $-7.74B | $4.20B | $-6.17B |
| Total Stockholders Equity | $6.07B | $6.11B | $5.76B | $6.04B | $6.00B |
| Total Equity | $6.07B | $6.11B | $5.76B | $6.04B | $6.28B |
| Total Liabilities and Stockholders Equity | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B |
| Minority Interest | $- | $- | $- | $- | $279.00M |
| Total Liabilities and Total Equity | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B |
| Total Investments | $108.00M | $359.00M | $161.00M | $275.00M | $250.00M |
| Total Debt | $1.32B | $14.23B | $13.01B | $12.44B | $12.90B |
| Net Debt | $-384.00M | $12.86B | $11.79B | $11.07B | $11.09B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.70B | $1.57B | $1.54B | $1.44B | $1.38B | $1.22B | $1.38B | $1.49B | $1.22B | $1.27B | $1.43B | $1.39B | $1.37B | $1.47B | $1.81B | $2.31B | $1.81B | $1.46B | $1.11B | $927.00M |
| Short Term Investments | $141.00M | $140.00M | $133.00M | $131.00M | $120.00M | $108.00M | $110.00M | $104.00M | $93.00M | $87.00M | $90.00M | $106.00M | $111.00M | $104.00M | $104.00M | $97.00M | $88.00M | $79.00M | $73.00M | $63.00M |
| Cash and Short Term Investments | $1.70B | $1.71B | $1.68B | $1.57B | $1.50B | $1.33B | $1.49B | $1.60B | $1.31B | $1.36B | $1.52B | $1.49B | $1.48B | $1.57B | $1.91B | $2.40B | $1.90B | $1.54B | $1.18B | $990.00M |
| Net Receivables | $3.80B | $3.25B | $3.30B | $3.46B | $3.41B | $3.28B | $3.18B | $3.10B | $2.96B | $2.69B | $2.72B | $2.66B | $2.61B | $2.39B | $2.35B | $2.42B | $2.47B | $2.49B | $2.42B | $2.68B |
| Inventory | $- | $- | $- | $- | $- | $177.00M | $179.00M | $165.00M | $151.00M | $176.00M | $188.00M | $162.00M | $156.00M | $164.00M | $178.00M | $159.00M | $159.00M | $165.00M | $146.00M | $173.00M |
| Other Current Assets | $331.00M | $670.00M | $648.00M | $615.00M | $687.00M | $600.00M | $653.00M | $625.00M | $712.00M | $704.00M | $670.00M | $617.00M | $677.00M | $574.00M | $812.00M | $752.00M | $722.00M | $610.00M | $602.00M | $604.00M |
| Total Current Assets | $5.83B | $5.63B | $5.62B | $5.65B | $5.60B | $5.21B | $5.33B | $5.33B | $4.98B | $4.75B | $4.91B | $4.77B | $4.76B | $4.53B | $5.07B | $5.58B | $5.09B | $4.64B | $4.21B | $4.28B |
| Property Plant Equipment Net | $773.00M | $772.00M | $768.00M | $791.00M | $819.00M | $790.00M | $829.00M | $845.00M | $863.00M | $840.00M | $899.00M | $938.00M | $903.00M | $889.00M | $900.00M | $909.00M | $953.00M | $942.00M | $946.00M | $934.00M |
| Goodwill | $14.71B | $15.09B | $14.48B | $14.52B | $14.57B | $14.29B | $14.18B | $14.02B | $13.92B | $13.18B | $13.10B | $13.53B | $13.30B | $13.12B | $12.55B | $12.41B | $12.65B | $12.36B | $12.13B | $11.99B |
| Intangible Assets | $4.50B | $4.73B | $4.61B | $4.72B | $4.84B | $4.91B | $4.94B | $4.76B | $4.82B | $4.72B | $4.73B | $4.92B | $4.94B | $4.81B | $4.77B | $4.92B | $5.21B | $5.22B | $5.26B | $5.33B |
| Goodwill and Intangible Assets | $19.21B | $19.82B | $19.09B | $19.24B | $19.41B | $19.20B | $19.12B | $18.77B | $18.74B | $17.89B | $17.84B | $18.45B | $18.24B | $17.94B | $17.32B | $17.33B | $17.86B | $17.59B | $17.39B | $17.32B |
| Long Term Investments | $108.00M | $320.00M | $287.00M | $263.00M | $241.00M | $214.00M | $208.00M | $201.00M | $162.00M | $151.00M | $159.00M | $162.00M | $164.00M | $158.00M | $158.00M | $162.00M | $162.00M | $163.00M | $153.00M | $143.00M |
| Tax Assets | $194.00M | $164.00M | $158.00M | $152.00M | $166.00M | $111.00M | $115.00M | $125.00M | $118.00M | $97.00M | $120.00M | $120.00M | $124.00M | $105.00M | $105.00M | $107.00M | $114.00M | $125.00M | $123.00M | $120.00M |
| Other Non-Current Assets | $786.00M | $467.00M | $478.00M | $476.00M | $453.00M | $459.00M | $435.00M | $468.00M | $472.00M | $488.00M | $487.00M | $528.00M | $491.00M | $411.00M | $385.00M | $380.00M | $386.00M | $377.00M | $358.00M | $287.00M |
| Total Non-Current Assets | $21.07B | $21.55B | $20.78B | $20.92B | $21.09B | $20.77B | $20.71B | $20.41B | $20.36B | $19.47B | $19.50B | $20.20B | $19.93B | $19.50B | $18.87B | $18.89B | $19.47B | $19.19B | $18.98B | $18.80B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $26.90B | $27.18B | $26.40B | $26.57B | $26.68B | $25.98B | $26.04B | $25.74B | $25.34B | $24.22B | $24.41B | $24.97B | $24.69B | $24.03B | $23.94B | $24.47B | $24.56B | $23.84B | $23.18B | $23.08B |
| Account Payables | $736.00M | $3.43B | $3.31B | $3.46B | $709.00M | $3.13B | $3.01B | $3.14B | $645.00M | $2.97B | $2.85B | $2.82B | $621.00M | $2.66B | $2.76B | $2.82B | $581.00M | $2.46B | $2.29B | $2.38B |
| Short Term Debt | $1.15B | $1.22B | $1.17B | $717.00M | $932.00M | $1.31B | $1.34B | $1.34B | $152.00M | $151.00M | $152.00M | $90.00M | $91.00M | $91.00M | $147.00M | $144.00M | $149.00M | $298.00M | $296.00M | $313.00M |
| Tax Payables | $156.00M | $161.00M | $185.00M | $155.00M | $116.00M | $172.00M | $208.00M | $187.00M | $161.00M | $124.00M | $118.00M | $135.00M | $137.00M | $53.00M | $101.00M | $135.00M | $102.00M | $101.00M | $102.00M | $94.00M |
| Deferred Revenue | $- | $1.82B | $1.81B | $1.91B | $1.80B | $1.84B | $1.84B | $1.83B | $1.80B | $1.84B | $1.81B | $1.93B | $1.82B | $1.83B | $1.60B | $1.55B | $1.25B | $1.19B | $1.06B | $1.04B |
| Other Current Liabilities | $4.92B | $354.00M | $144.00M | $207.00M | $2.94B | $137.00M | $140.00M | $157.00M | $2.82B | $165.00M | $177.00M | $189.00M | $2.57B | $214.00M | $218.00M | $216.00M | $2.47B | $91.00M | $89.00M | $80.00M |
| Total Current Liabilities | $6.96B | $6.99B | $6.62B | $6.45B | $6.49B | $6.59B | $6.54B | $6.66B | $5.58B | $5.25B | $5.10B | $5.16B | $5.24B | $4.85B | $4.82B | $4.87B | $4.56B | $4.14B | $3.84B | $3.91B |
| Long Term Debt | $346.00M | $12.48B | $12.28B | $13.02B | $13.41B | $12.54B | $12.68B | $12.09B | $13.08B | $12.50B | $12.90B | $12.86B | $12.52B | $12.40B | $12.48B | $12.44B | $12.88B | $12.58B | $12.37B | $12.26B |
| Deferred Revenue Non-Current | $- | $- | $192.00M | $204.00M | $451.00M | $- | $- | $- | $464.00M | $560.00M | $494.00M | $- | $410.00M | $- | $- | $- | $338.00M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $196.00M | $128.00M | $149.00M | $164.00M | $202.00M | $365.00M | $367.00M | $421.00M | $464.00M | $560.00M | $494.00M | $455.00M | $410.00M | $297.00M | $266.00M | $337.00M | $338.00M | $429.00M | $539.00M | $618.00M |
| Other Non-Current Liabilities | $13.33B | $612.00M | $632.00M | $595.00M | $470.00M | $679.00M | $703.00M | $641.00M | $447.00M | $561.00M | $563.00M | $581.00M | $62.00M | $656.00M | $607.00M | $586.00M | $173.00M | $580.00M | $582.00M | $491.00M |
| Total Non-Current Liabilities | $13.88B | $13.22B | $13.06B | $13.78B | $14.08B | $13.58B | $13.74B | $13.15B | $13.99B | $13.62B | $13.96B | $13.89B | $13.41B | $13.36B | $13.36B | $13.36B | $13.73B | $13.59B | $13.49B | $13.37B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $20.83B | $20.21B | $19.68B | $20.23B | $20.57B | $20.17B | $20.29B | $19.81B | $19.57B | $18.88B | $19.06B | $19.05B | $18.65B | $18.20B | $18.18B | $18.23B | $18.28B | $17.73B | $17.33B | $17.28B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $11.14B | $3.00M | $3.00M | $3.00M | $3.00M | $10.99B | $10.95B | $10.91B | $10.90B | $10.85B | $10.79B | $10.74B | $10.78B | $10.75B | $10.70B | $11.07B | $11.10B | $11.07B | $11.04B | $11.01B |
| Retained Earnings | $6.07B | $5.63B | $5.34B | $4.98B | $4.69B | $4.22B | $3.92B | $3.62B | $3.33B | $3.11B | $2.82B | $2.57B | $2.24B | $1.93B | $1.66B | $1.49B | $1.28B | $1.16B | $1.06B | $1.08B |
| Accumulated Other Comprehensive Income Loss | $-1.04B | $-826.00M | $-949.00M | $-911.00M | $-867.00M | $-903.00M | $-760.00M | $-731.00M | $-727.00M | $-898.00M | $-697.00M | $-419.00M | $-406.00M | $-445.00M | $-327.00M | $-376.00M | $-205.00M | $-317.00M | $-444.00M | $-485.00M |
| Other Total Stockholders Equity | $-10.10B | $2.16B | $2.32B | $2.27B | $2.28B | $-8.51B | $-8.36B | $-7.87B | $-7.74B | $-7.71B | $-7.57B | $-6.97B | $4.20B | $-6.40B | $-6.27B | $-6.23B | $-6.17B | $-6.07B | $-6.07B | $-6.07B |
| Total Stockholders Equity | $6.07B | $6.97B | $6.71B | $6.34B | $6.11B | $5.80B | $5.75B | $5.93B | $5.76B | $5.35B | $5.35B | $5.92B | $6.04B | $5.83B | $5.76B | $5.95B | $6.00B | $5.85B | $5.59B | $5.54B |
| Total Equity | $6.07B | $6.97B | $6.71B | $6.34B | $6.11B | $5.80B | $5.75B | $5.93B | $5.76B | $5.35B | $5.35B | $5.92B | $6.04B | $5.83B | $5.76B | $6.24B | $6.28B | $6.11B | $5.85B | $5.80B |
| Total Liabilities and Stockholders Equity | $26.90B | $27.18B | $26.40B | $26.57B | $26.68B | $25.98B | $26.04B | $25.74B | $25.34B | $24.22B | $24.41B | $24.97B | $24.69B | $24.03B | $23.94B | $24.47B | $24.56B | $23.84B | $23.18B | $23.08B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $284.00M | $279.00M | $261.00M | $261.00M | $260.00M |
| Total Liabilities and Total Equity | $26.90B | $27.18B | $26.40B | $26.57B | $26.68B | $25.98B | $26.04B | $25.74B | $25.34B | $24.22B | $24.41B | $24.97B | $24.69B | $24.03B | $23.94B | $24.47B | $24.56B | $23.84B | $23.18B | $23.08B |
| Total Investments | $108.00M | $460.00M | $420.00M | $394.00M | $361.00M | $99.00M | $101.00M | $206.00M | $161.00M | $238.00M | $249.00M | $268.00M | $275.00M | $262.00M | $262.00M | $259.00M | $250.00M | $242.00M | $226.00M | $134.00M |
| Total Debt | $1.32B | $13.70B | $13.45B | $13.74B | $14.23B | $13.85B | $14.02B | $13.43B | $13.01B | $12.65B | $13.05B | $12.95B | $12.44B | $12.49B | $12.63B | $12.58B | $12.90B | $12.73B | $12.51B | $12.40B |
| Net Debt | $-384.00M | $12.13B | $11.90B | $12.30B | $12.86B | $12.62B | $12.64B | $11.94B | $11.79B | $11.38B | $11.62B | $11.56B | $11.07B | $11.03B | $10.82B | $10.28B | $11.09B | $11.26B | $11.40B | $11.47B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $1.37B | $1.36B | $1.09B | $971.00M | $308.00M |
| Depreciation and Amortization | $1.11B | $1.12B | $1.13B | $1.26B | $1.29B |
| Deferred Income Tax | $-129.00M | $-269.00M | $-115.00M | $-138.00M | $-176.00M |
| Stock Based Compensation | $206.00M | $217.00M | $194.00M | $170.00M | $95.00M |
| Change in Working Capital | $158.00M | $-280.00M | $-84.00M | $680.00M | $459.00M |
| Accounts Receivables | $182.00M | $-388.00M | $-421.00M | $-138.00M | $255.00M |
| Inventory | $- | $- | $- | $-17.00M | $-229.00M |
| Accounts Payables | $115.00M | $267.00M | $427.00M | $244.00M | $253.00M |
| Other Working Capital | $-139.00M | $-159.00M | $-90.00M | $591.00M | $180.00M |
| Other Non Cash Items | $-6.00M | $-2.00M | $44.00M | $-5.00M | $-14.00M |
| Net Cash Provided by Operating Activities | $2.72B | $2.15B | $2.26B | $2.94B | $1.96B |
| Investments in Property Plant and Equipment | $- | $-649.00M | $-674.00M | $-640.00M | $-616.00M |
| Acquisitions Net | $-735.00M | $-876.00M | $-1.33B | $-1.46B | $-167.00M |
| Purchases of Investments | $-2.00M | $-83.00M | $-5.00M | $-10.00M | $-11.00M |
| Sales Maturities of Investments | $- | $- | $- | $5.00M | $-2.00M |
| Other Investing Activities | $-707.00M | $5.00M | $8.00M | $5.00M | $-2.00M |
| Net Cash Used for Investing Activities | $-1.44B | $-1.60B | $-2.01B | $-2.10B | $-796.00M |
| Debt Repayment | $553.00M | $802.00M | $941.00M | $70.00M | $342.00M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-1.35B | $-992.00M | $-1.17B | $-406.00M | $-447.00M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-81.00M | $-192.00M | $-102.00M | $-899.00M | $-112.00M |
| Net Cash Used Provided by Financing Activities | $-878.00M | $-382.00M | $-329.00M | $-1.24B | $-217.00M |
| Effect of Forex Changes on Cash | $-68.00M | $-4.00M | $-75.00M | $-52.00M | $31.00M |
| Net Change in Cash | $326.00M | $160.00M | $-150.00M | $-448.00M | $977.00M |
| Cash at End of Period | $1.70B | $1.38B | $1.22B | $1.37B | $1.81B |
| Cash at Beginning of Period | $1.38B | $1.22B | $1.37B | $1.81B | $837.00M |
| Operating Cash Flow | $2.72B | $2.15B | $2.26B | $2.94B | $1.96B |
| Capital Expenditure | $- | $-649.00M | $-674.00M | $-640.00M | $-616.00M |
| Free Cash Flow | $2.72B | $1.50B | $1.59B | $2.30B | $1.34B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $437.00M | $285.00M | $363.00M | $288.00M | $469.00M | $303.00M | $297.00M | $289.00M | $227.00M | $283.00M | $256.00M | $325.00M | $318.00M | $261.00M | $175.00M | $217.00M | $130.00M | $108.00M | $-21.00M | $91.00M |
| Depreciation and Amortization | $303.00M | $278.00M | $269.00M | $264.00M | $316.00M | $297.00M | $259.00M | $253.00M | $357.00M | $248.00M | $270.00M | $255.00M | $262.00M | $336.00M | $343.00M | $323.00M | $344.00M | $319.00M | $308.00M | $316.00M |
| Deferred Income Tax | $-15.00M | $-34.00M | $-14.00M | $-66.00M | $-152.00M | $-47.00M | $-43.00M | $-27.00M | $-63.00M | $-24.00M | $-18.00M | $-10.00M | $-55.00M | $-40.00M | $-4.00M | $-39.00M | $-16.00M | $-58.00M | $-62.00M | $-40.00M |
| Stock Based Compensation | $48.00M | $54.00M | $48.00M | $56.00M | $45.00M | $47.00M | $50.00M | $75.00M | $58.00M | $61.00M | $45.00M | $30.00M | $42.00M | $48.00M | $48.00M | $32.00M | $26.00M | $33.00M | $15.00M | $2.00M |
| Change in Working Capital | $105.00M | $151.00M | $-82.00M | $-16.00M | $73.00M | $-22.00M | $-156.00M | $-175.00M | $-5.00M | $278.00M | $-246.00M | $-111.00M | $130.00M | $235.00M | $-15.00M | $330.00M | $268.00M | $173.00M | $227.00M | $-209.00M |
| Accounts Receivables | $-77.00M | $72.00M | $122.00M | $65.00M | $-254.00M | $-107.00M | $-27.00M | $-107.00M | $-278.00M | $55.00M | $-197.00M | $54.00M | $-801.00M | $182.00M | $139.00M | $342.00M | $-73.00M | $120.00M | $292.00M | $-84.00M |
| Inventory | $- | $- | $- | $- | $121.00M | $- | $- | $- | $- | $- | $- | $- | $-17.00M | $- | $- | $- | $-229.00M | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $267.00M | $- | $- | $- | $427.00M | $- | $- | $- | $244.00M | $- | $- | $- | $253.00M | $- | $- | $- |
| Other Working Capital | $182.00M | $79.00M | $-82.00M | $-16.00M | $-61.00M | $85.00M | $-129.00M | $-68.00M | $-154.00M | $223.00M | $-49.00M | $-165.00M | $704.00M | $53.00M | $-154.00M | $-12.00M | $317.00M | $53.00M | $-65.00M | $-125.00M |
| Other Non Cash Items | $7.00M | $-13.00M | $590.00M | $580.00M | $-4.00M | $5.00M | $-5.00M | $2.00M | $-14.00M | $17.00M | $22.00M | $19.00M | $-5.00M | $4.00M | $-8.00M | $4.00M | $-2.00M | $-1.00M | $5.00M | $3.00M |
| Net Cash Provided by Operating Activities | $885.00M | $721.00M | $588.00M | $522.00M | $747.00M | $583.00M | $402.00M | $417.00M | $560.00M | $863.00M | $329.00M | $508.00M | $692.00M | $844.00M | $539.00M | $867.00M | $750.00M | $574.00M | $472.00M | $163.00M |
| Investments in Property Plant and Equipment | $-164.00M | $-150.00M | $-143.00M | $-145.00M | $-179.00M | $-146.00M | $-160.00M | $-164.00M | $-171.00M | $-165.00M | $-161.00M | $-177.00M | $-184.00M | $-162.00M | $-145.00M | $-149.00M | $-176.00M | $-157.00M | $-142.00M | $-141.00M |
| Acquisitions Net | $-150.00M | $-447.00M | $-54.00M | $-142.00M | $-7.00M | $-428.00M | $-432.00M | $-25.00M | $-309.00M | $-552.00M | $-38.00M | $-436.00M | $-466.00M | $-929.00M | $-48.00M | $-20.00M | $-57.00M | $-33.00M | $-80.00M | $3.00M |
| Purchases of Investments | $- | $- | $-24.00M | $-27.00M | $-27.00M | $-3.00M | $-6.00M | $-40.00M | $-1.00M | $-1.00M | $-4.00M | $-3.00M | $-1.00M | $-1.00M | $-2.00M | $-8.00M | $-1.00M | $-1.00M | $4.00M | $-13.00M |
| Sales Maturities of Investments | $- | $- | $- | $- | $-38.00M | $3.00M | $6.00M | $- | $- | $- | $42.00M | $- | $9.00M | $-4.00M | $9.00M | $- | $-2.00M | $- | $- | $- |
| Other Investing Activities | $4.00M | $-2.00M | $1.00M | $-27.00M | $39.00M | $1.00M | $-4.00M | $7.00M | $4.00M | $1.00M | $-38.00M | $3.00M | $-5.00M | $1.00M | $8.00M | $1.00M | $-1.00M | $-8.00M | $-1.00M | $1.00M |
| Net Cash Used for Investing Activities | $-310.00M | $-599.00M | $-221.00M | $-314.00M | $-212.00M | $-573.00M | $-596.00M | $-222.00M | $-477.00M | $-717.00M | $-199.00M | $-613.00M | $-647.00M | $-1.09B | $-185.00M | $-176.00M | $-236.00M | $-191.00M | $-219.00M | $-150.00M |
| Debt Repayment | $783.00M | $66.00M | $-253.00M | $-43.00M | $-155.00M | $9.00M | $612.00M | $336.00M | $-123.00M | $-39.00M | $477.00M | $626.00M | $77.00M | $36.00M | $-36.00M | $-7.00M | $-97.00M | $-36.00M | $-40.00M | $515.00M |
| Common Stock Issued | $- | $- | $-60.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-1.15B | $-200.00M | $- | $- | $-229.00M | $-144.00M | $-490.00M | $-129.00M | $-65.00M | $-210.00M | $-490.00M | $-403.00M | $-204.00M | $-95.00M | $-45.00M | $-62.00M | $-101.00M | $- | $-1.00M | $-345.00M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-8.00M | $-3.00M | $-7.00M | $-63.00M | $-36.00M | $-9.00M | $-27.00M | $-120.00M | $-5.00M | $-2.00M | $-16.00M | $-79.00M | $-11.00M | $-7.00M | $-782.00M | $-99.00M | $- | $-17.00M | $-32.00M | $-63.00M |
| Net Cash Used Provided by Financing Activities | $-375.00M | $-137.00M | $-260.00M | $-106.00M | $-420.00M | $-144.00M | $95.00M | $87.00M | $-193.00M | $-251.00M | $-29.00M | $144.00M | $-138.00M | $-66.00M | $-863.00M | $-168.00M | $-198.00M | $-53.00M | $-73.00M | $107.00M |
| Effect of Forex Changes on Cash | $-70.00M | $42.00M | $-6.00M | $-34.00M | $37.00M | $-24.00M | $-13.00M | $-4.00M | $52.00M | $-49.00M | $-60.00M | $-18.00M | $-11.00M | $-20.00M | $11.00M | $-32.00M | $34.00M | $25.00M | $2.00M | $-30.00M |
| Net Change in Cash | $130.00M | $27.00M | $101.00M | $68.00M | $152.00M | $-158.00M | $-112.00M | $278.00M | $-58.00M | $-154.00M | $41.00M | $21.00M | $-104.00M | $-337.00M | $-498.00M | $491.00M | $350.00M | $355.00M | $182.00M | $90.00M |
| Cash at End of Period | $1.70B | $1.57B | $1.54B | $1.44B | $1.38B | $1.22B | $1.38B | $1.49B | $1.22B | $1.27B | $1.43B | $1.39B | $1.37B | $1.47B | $1.81B | $2.31B | $1.81B | $1.46B | $1.11B | $927.00M |
| Cash at Beginning of Period | $1.57B | $1.54B | $1.44B | $1.38B | $1.22B | $1.38B | $1.49B | $1.22B | $1.27B | $1.43B | $1.39B | $1.37B | $1.47B | $1.81B | $2.31B | $1.81B | $1.46B | $1.11B | $927.00M | $837.00M |
| Operating Cash Flow | $885.00M | $721.00M | $588.00M | $522.00M | $747.00M | $583.00M | $402.00M | $417.00M | $560.00M | $863.00M | $329.00M | $508.00M | $692.00M | $844.00M | $539.00M | $867.00M | $750.00M | $574.00M | $472.00M | $163.00M |
| Capital Expenditure | $-164.00M | $-150.00M | $-143.00M | $-145.00M | $-179.00M | $-146.00M | $-160.00M | $-164.00M | $-171.00M | $-165.00M | $-161.00M | $-177.00M | $-184.00M | $-162.00M | $-145.00M | $-149.00M | $-176.00M | $-157.00M | $-142.00M | $-141.00M |
| Free Cash Flow | $721.00M | $571.00M | $445.00M | $377.00M | $568.00M | $437.00M | $242.00M | $253.00M | $389.00M | $698.00M | $168.00M | $331.00M | $508.00M | $682.00M | $394.00M | $718.00M | $574.00M | $417.00M | $330.00M | $22.00M |
IQVIA Holdings Dividends
Explore IQVIA Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
IQVIA Holdings News
Read the latest news about IQVIA Holdings, including recent articles, headlines, and updates.
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio.
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.
IQVIA Releases 2024 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years.
IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call.
IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded o.
IQVIA named to the Fortune® World's Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on fou.
Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Iqvia initiated with an Overweight at Stephens
Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company's Q3 reset, as well as the recent outline of "reasonably conservative" fiscal 2025 and long-term growth frameworks, as creating an attractive setup "for a well-run industry bellwether."
IQVIA Holdings: Share Price Disconnected From Growth Outlook
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for IQV.